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Purpose: In this systematic review and meta-analysis, we aimed to estimate cancer-specific 
mortality and all-cause mortality among cancer survivors associated with both short (typically 5 
or 6 h/night) and long (typically 9 or 10 h/night) sleep duration (versus recommendations), 
separately by sex, cancer site, and sampling frame. Methods: We completed a systematic 
literature search in five databases and captured relevant literature published through December 
2018. Two reviewers independently screened 9,823 records and 32 studies were included 
representing over 73,000 deaths in cancer survivors. Estimates for short and long sleep duration 
compared to ‘recommended’ were pooled using random-effects models. Results: Pooled hazards 
ratios for short and long sleep duration for all-cancer-specific mortality were 1.03 (95% CI 1.00–
1.06) and 1.09 (95% CI 1.04–1.13), respectively. In subgroup analyses by cancer site, 
statistically significant increased risks were found for both short and long sleep durations for 
lung cancer-specific mortality. These associations were maintained when stratified by sex and 
sampling frame. There were no statistically significant associations found between either short or 
long sleep duration and breast, colorectal, ovarian, or prostate cancer-specific mortality. 
Statistically significant increases in all-cause mortality were observed with long sleep duration in 
breast cancer survivors (1.38; 95% CI 1.16–1.64) with no significant associations found for 
colorectal or liver/pancreatic cancers. Conclusions: We observed that long sleep duration 
increases cancer-specific mortality for all-cancers and lung cancers, while all-cause mortality is 
increased for breast cancer survivors. Limitations were found within the existing literature that 
need to be addressed in future studies in order to improve the understanding regarding the exact 
magnitude of the effect between sleep duration and site-specific mortality. 
 






Evidence suggests that both short and long sleep durations are associated with a plethora of 
adverse outcomes [1, 2] including all-cause mortality [3,4,5], Type II diabetes [6], cardiovascular 
events and disease outcomes [4, 7, 8], cancer risk [9], and cancer-specific mortality [10]. Recent 
findings suggest that sleep is disturbed in cancer patients and survivors [11,12,13,14] and that 
sleep disruption in cancer patients and survivors can lead to increased risk of morbidity, 
mortality, and poor quality of life [12]. Inconsistent results have been found in observational 
studies regarding the association between sleep duration and cancer mortality. Some studies have 
observed a U-shaped association [15], while other studies have observed associations for long 
but not short sleep durations [16, 17] or no association [18]. These inconsistencies warrant 
further investigation of the effects of sleep duration on cancer-specific mortality, given the 
growing amount of evidence that remains inconsistent regarding the nature of these associations. 
Additionally, with more published evidence that has provided site- and sex-specific estimates, it 
is important to investigate whether or not typical sleep duration is associated with mortality for 
individual cancer sites rather than all-cancer sites combined, and if sex acts as an effect modifier 
with different magnitudes of association found in men and women. The rationale for providing 
these separate estimates is that each cancer site has a different etiology and mortality rate. While 
precise biological mechanisms remain to be elucidated, inflammatory processes [19,20,21], 
oxidative stress [22], and suppressed melatonin [23] have been proposed. Though sleep 
disruption does not necessarily indicate specifically short or long duration sleepers, it has been 
suggested that sleep disruption can lead to systemic inflammation, which has been linked to 
tumor progression, cancer aggressiveness, and recurrence, which may also be mechanisms 
linking sleep duration to these outcomes [12, 24, 25]. 
 
Two meta-analyses related to sleep duration and cancer mortality have been conducted to date 
[5, 10]. The first found an association for long, but not short, sleep duration on the risk of cancer 
mortality, though it was limited to three studies and may have lacked statistical power to find an 
effect [5]. Similarly, the second meta-analysis of prospective studies investigating the relation 
between cancer mortality and sleep duration found that long sleep duration (≥ 9–10 h; RR = 1.11, 
95% CI 1.05–1.19), but not short sleep duration (≤ 5–6 h; RR = 1.05, 95% CI 0.99–1.11), was 
associated with total cancer mortality [10]. Since 2015, 15 papers from large prospective studies 
have been published on the topic, including six conducted within cohorts of cancer survivors. 
Moreover, neither of the reviews mentioned investigated the effect of sleep duration on all-cause 
mortality or were able to investigate cancer-specific mortality by cancer site. 
 
To clarify the relation between short and long sleep duration on cancer mortality, we conducted a 
systematic review and meta-analysis of prospective observational studies. The aim of this meta-
analysis was to investigate the risk of all-cause mortality in cancer survivors and cancer-specific 
mortality for both long (typically > 8–10 h) and short (typically < 5–7 h) sleep duration compared 
to reference sleep duration ranges, typically defined as 7–8 h per night for older adults [26]. 
Secondary aims were to explore subgroup analyses investigating these relations by both sex and 




The systematic review protocol was registered in PROSPERO (registration number: 
CRD42017078468). 
 
Literature search strategy 
 
Five databases were searched through 31 October 2017 including PubMed, MEDLINE OVID, 
EMBASE, CINAHL, and PsycINFO using the following search strategy: ((sleep* OR sleep/OR 
“sleep duration” OR “sleep deprivation” OR “sleep time”) AND (cancer OR cancer/OR 
neoplasm OR carcinoma OR tumour OR tumor) AND (mortality OR survival OR death OR 
recurrence OR progression OR outcome* OR fatal)). Keywords (including any associated 
synonyms) along with medical subject headings for cancer, sleep, and mortality were included in 
the search. There were no restrictions by type or site of cancer, language, date, or geographical 
region. Moreover, reference lists of relevant review articles and all included studies were 
searched manually to identify any additional studies for inclusion, and reverse citation searches 
were conducted for all included studies. Additionally, e-alert notifications were established for 




The following predetermined inclusion criteria were applied: (i) an observational study design; 
(ii) short or long sleep duration as the exposure of interest; (iii) all-cause or cancer-specific 
mortality as the outcome of interest; (iv) night time sleep duration, not restricted to those with 
sleep-related disorders or insomnia; and (v) risk estimates (risk ratios (RRs)/hazards ratios 
(HRs)) with corresponding 95% confidence intervals (95% CIs). The PRISMA flow diagram 
documenting all phases of literature search is provided in Fig. 1. In brief, all duplicates were 
removed and titles and abstracts were screened in duplicate by two independent reviewers (C.R.S 
and T.R.H) and excluded if they were (1) not on topic; or (2) not original research (i.e., reviews 
pertaining to sleep and cancer). The two reviewers then independently screened the full-text 
articles of abstracts identified in the first stage of review. Articles were excluded if they were (1) 
not on topic; (2) not original article (i.e., conference abstract, review, commentary); (3) results 
were not presented and authors could not be reached to obtain said results; or (4) the source 
population used in the study had been previously published (i.e., duplicate populations). 
Discrepancies were resolved by discussion and confirmed by a third author (J.M). 
 
 




A data-extraction form was created specifically for this review and was pilot tested by co-authors 
(T.R.H and C.R.S). Extraction was conducted independently (C.R.S) and verified by another 
reviewer (T.R.H). The form was used to extract the following information from each study: first 
author’s last name, year of publication, study country, study/cohort name, recruitment dates, 
follow-up duration, study population age, distribution by sex, number of participants and number 
of cancer deaths, participant source, and mortality ascertainment. Additionally, information was 
extracted on data capture methods and definitions of sleep duration, and sub-groups based on 
age, sex, or cancer site. Statistical model covariate adjustment factors and corresponding risk 
estimates HRs or RRs and 95% CIs for shortest and longest levels of sleep duration with all-
cause and cancer-specific mortality associated were extracted. We contacted five authors by e-
mail up to two times to request results where estimates were not presented. Four authors replied, 
and three were able to provide additional information required for inclusion in our review. 
 
Study quality assessment 
 
Study quality was assessed using the Newcastle–Ottawa Scale for observational cohort studies 
[27]. This scale includes three domains: selection, comparability, and outcome. The elements on 
this scale include (i) assessment of the representativeness of the sample selection (cases and 
controls); (ii) ascertainment method of the exposure; (iii) demonstration that the outcome was 
not present at study start; (iv) important control of known covariates compared to other similar 
studies; (v) assessment method of the outcome; (vi) sufficiency of length of follow-up; and (vii) 
adequacy of follow-up (attrition/loss-to-follow-up). A full description of each item is presented 




Risk estimates were obtained from the most fully adjusted multivariate models within each of the 
studies. Sex and cancer site-specific estimates were considered independent reports in studies 
that reported specific subgroup results and these estimates were extracted as well as those for the 
overall study population. The pooled HRs with 95% CIs were obtained using a random-effects 
model since it was assumed that the included studies will differ because of random error and 
between study variability [28]. Potential sources of heterogeneity by sex and study sampling 
frame (i.e., studies with reported healthy cohorts at baseline versus studies incorporating 
individuals with pre-existing cancer diagnoses) were explored within cancer sites using subgroup 
and meta-regression analyses within cancer-specific mortality where appropriate. We estimated 
and quantified heterogeneity using the Cochran Q test and I2 statistics [29]. The following cut-off 
points were used for the I2 statistic: < 25% (indicating little or no heterogeneity), 25–75% 
(moderate heterogeneity), and > 75% (high heterogeneity) [30]. The Begg’s rank correlation [31] 
and Egger’s linear regression [32] tests were used to investigate any potential publication bias. 
All statistical analyses were performed using STATA software, version 14.2 (STATA Corp., 





Search results and study characteristics 
 
We identified 9,824 records from our database search, four from searching reference lists and 
four from updated e-alert notifications (Fig. 1). After removing duplicates, 6,030 titles/abstracts 
remained that were screened by two independent reviewers. Seven hundred and sixty-seven 
records were eligible for full-text screening, that resulted in 99.74% agreement on 
inclusion/exclusion (κ = 0.96) achieved after independent review. A total of 32 records qualified 
for final inclusion in this systematic review, and 30 records were included in the meta-analysis. 
 




Name of study, 
country 
Population 



















duration Adjusted covariates 
Mallon, 2002 
[42] 
NR, Sweden 45–65 years 12 years 1,870 83 Cancer-specific 
male (all), female 
(all)a 
Unclear > 8 h < 6 h 6–8 h Age 
Amagai, 2004 
[33] 
Jichi Medical School 
Cohort Study, Japan 
30–69 years 9 years 11,325 201 Cancer-specific 




> 9 h < 5.9 h 7–7.9 h Age, BMI, systolic blood pressure, total cholesterol, 
smoking, alcohol drinking, education, and marital status 
Patel, 2004 
[45] 
Nurses’ Health Study 
(NHS), USA 
30–55 years 14 years 82,969 2,642 Cancer-specific 
female (all)a 
Unclear > 9 h ≤ 5 h 7 h Age, BMI, smoking, alcohol drinking, physical activity, 




Survey of Health and 
Living Status of the 
Elderly, Taiwan 
≥ 64 years 10 years 3,079 278 Cancer-specific 
male (all), female 
(all) 
Unclear ≥ 10 h < 7 h 7–7.9 h Age, BMI, marital status, monthly income, smoking, 





Study for Evaluation 
of Cancer Risk 
(JACC), Japan 
40–79 years 15 years 109,778 6,219 Cancer-specific 
male (all) and 
female (all), and 
cancer site by sex 
Unclear > 9 h < 7 h 7–8 h Age and area of study 
Stone, 2009 
[55] 




≥ 69 years 8 years 8,101 423 Cancer-specific 
female (all) 
Unclear ≥ 10 h NE 8 to < 9 h Age, BMI, history of various medical conditions (including 
chronic diseases and cancer), walks for exercise, alcohol 
use, smoking status, depression, cognitive impairment, 





(NHI) Cohort Study, 
Japan 
40–79 years 13 years 51,253 2,764 Cancer-specific 
overall 
Unclear ≥ 10 h ≤ 6 h 7 h Age, sex, BMI, total caloric intake, marital status, 
education, job status, myocardial infarction, stroke, 
hypertension, diabetes mellitus, smoking, alcohol drinking, 
time spent walking, perceived mental stress, self-rated 




Cohort (MEC) Study, 
USA 
45–75 years 14 years 135,685 6,772 Cancer-specific 




≥ 9 h ≤ 5 h 7 h 5-year age groups at cohort entry, ethnicity, education, 
marital status, history of hypertension or diabetes at 
enrollment, alcohol consumption, energy intake, body mass 
index, physical activity, hours spent daily watching 





(KMCC) Study, Korea 
≥ 20 years 17 years 13,164 526 Cancer-specific 
overall, male (all), 
Unclear ≥ 10 h ≤ 5 h 7 h Age, BMI, education, smoking, alcohol drinking, 





Name of study, 
country 
Population 



















duration Adjusted covariates 
female (all), < 60 y 
(all), ≥ 60 y (all) 
Bellavia, 
2014 [35] 
Cohort of Swedish 
Men and the Swedish 
Mammography 
Cohort, Sweden 




> 8 h < 6 h 6.6–7.4 h Age at baseline, sex, BMI, smoking status and pack-years 
of smoking, alcohol consumption, and educational level, 










9–12 h 3–5 h 7 h Oral contraceptive use, age at menarche and menopause, 
tubal ligation, parity, postmenopausal estrogen use, race, 











10–12 h 3–5 h 7 h Age, race, education, BMI, smoking status, family history 








8–9 h < 7 h 7–8 h Age, estrogen receptor status, treatment, dominant site of 
metastatic disease spread, depression, and cortisol levels 
Rod, 2014 
[46] 
Whitehall II Cohort 
Study, UK 
35–55 years 25 years 9,098 374 Cancer-specific 




> 9 h ≤ 6 h 7–8 h Age, employment grade, ethnicity, and marital status 
Xiao, 2014 
[49] 
NIH-AARP Diet and 
Health Study, USA 





≥ 9 h < 5 h 7–8 h Age, sex, BMI, ethnicity, marital status, education, self-
reported health, smoking, alcohol consumption, moderate-
vigorous physical activity, and TV Viewing. Excluded 




Health Study and 
Shanghai Men’s 
Health Study, China 
40–79 years 13 years 113,138 NR Cancer-specific 
overall, male (all), 
female (all), cancer 
site 
Unclear ≥ 10 h < 6 h 7 h Education, income, smoking, alcohol consumption, tea 
consumption, comorbidity score, history of night-shift 
work, participation in regular exercise, body mass index, 
and waist-to-hip ratio 
Markt, 2015 
[43] 
The National March 
Cohort (NMC), 
Sweden 




≥ 9 h ≤ 5 h 8 h BMI, employment status, snoring, smoking, alcohol use, 
depressive symptoms, physical activity, coffee intake, 




Cohort Study, China 
63.6 years 5 years 25,377 379 Cancer-specific 




≥ 10 h < 7 h 7–8 h Age, BMI, family history of cancer, alcohol drinking and 
smoking status, and pack-year 
Dickerman, 
2016 [56] 
The Older Finnish 
Twin Cohort, Finland 




> 8 h NE < 7 h Age, education, BMI, physical activity, social class, 




Name of study, 
country 
Population 





























> 10 h ≤ 5 h 8 h Age, race, vigorous activity level, smoking, diabetes, 
family history of prostate cancer, snoring status, 
multivitamin use, energy intake, history of PSA testing, 
beta-blocker use, marital status, coffee intake, alcohol 




The Women’s Health 
Initiative (WHI), USA 
50–79 21 years 21,230 4,482 Cancer-specific 




≥ 9 h ≤ 5 h 7–8 h Age at enrollment, study arm, cancer site, marital status, 
household income, smoking history, recreational physical 





Fractures in Men 
Sleep Study, USA 
> 65 7.4 years 
(average) 
2,531 171 Cancer-specific 
male (all) 
Unclear > 8 h < 5 h 5–8 h Age, study site, race, body mass index, probable 
depression, cognition, alcohol use, education, smoking 
status, caffeine use, physical activity, chronic disease, self-




The Swedish National 
March, Sweden 
≥ 18 13 years 39,191 1,645 Cancer-specific 
overall 
Unclear ≥ 8 h ≤ 5 h 7 h Age, sex, BMI, smoking status, alcohol consumption, 









≥ 9 h < 6.5 h 7.5 h Age, gender, education, diagnosis, vascular invasion, 




The Women’s Healthy 
Eating and Living 
(WHEL) Study, USA 





≥ 9 h ≤ 6 h 7–8 h Age, stage, grade, body mass index, number of 





NR, Germany 69 years 
(median) 
12 years 1,376 200 All-cause colorectal Post-
diagnosis 
≥ 9 h ≤ 6 h 7–8 h Sex, age at physical activity assessment, BMI, survival 
time from CRC diagnosis until physical activity 
assessment, tumor location, occurrence of metastases, 
occurrence of other cancer, chemotherapy, smoking status, 






Nurses’ Health Study 
(NHS), USA 





≥ 9 h ≤ 6 h 8 h Year of diagnosis, age at diagnosis, time since diagnosis, 
cancer stage, surgery, chemotherapy, radiation therapy, 
hormone therapy, prevalent diabetes or heart disease, 
missing indicators for oncologic treatments, age, marital 
status, education level, income, OC use, number of 
pregnancies, family history of breast cancer, menopausal 




Name of study, 
country 
Population 



















duration Adjusted covariates 
Wong, 2017 
[15] 
The Xuanwei Cohort 
Study of farmers, 
China 
> 21 years 19 years 42,422 4,829 Cancer-specific 





≥ 10 h ≤ 7 h 8 h Average hours spent performing indoor activities in the 
same age period as sleep, type of respondent, other work 
besides farming, educational attainment, duration of 
smoking, ever active smoking, ethnicity, average number of 
rooms and people in residences from 1976 to 1992, fuel 
type used in first residence, installation of a chimney for 
ventilation, family history of any cancer, average tons of 
fuel/coal used from 1976 to 1992, ever employment as a 




NIH-AARP Diet and 
Health Study, USA 




> 9 h < 5 h 7–8 h Age at diagnosis, sex, cancer site, tumor stage, tumor 
grade, surgery, chemotherapy, radiation, education, 
smoking, TV viewing, MVPA, BMI, self-reported health, 
history of heart disease, history of stroke, history of 
diabetes and napping 
Kabat, 2018 
[53] 
The Women’s Health 
Initiative (WHI), USA 




≥ 10 h ≤ 5 h 7 h Age, smoking status, pack-years of smoking, alcohol 
intake, hormone therapy, body mass index, red meat intake, 
physical activity, marital status, depression, history of 
diabetes, history of cancer, history of cardiovascular 
disease, systolic blood pressure, health status, educational 
level, ethnicity, and study participation 
Khan, 2018 
[57] 
The Kuopio Ischemic 
Heart Disease Study, 
Finland 




> 10.2 h NE < 8 Age, diabetes, smoking, alcohol use, BMI, systolic blood 
pressure, serum creatinine and serum LDL-c, physical 




Chinese Health Study, 
Singapore 
45–74 years 22 years 39,523 1,989 Cancer-specific 
overall 
Unclear ≥ 9 h ≤ 5 h 7 h Age, year of recruitment, gender, dialect group, physical 
activity, level of education, smoking status, alcohol intake, 
body mass index, history of hypertension, ischemic heart 
disease, stroke, diabetes, and cancer 
NR not reported, NE not evaluated, BMI body mass index, CVD cardiovascular disease, OC oral contraception, PMH postmenopausal hormone 
aIndicates use of RR rather than HR 
Study characteristics for the 32 included studies are presented in Table 1. Ultimately, 26 studies 
reported estimates for short sleep duration and cancer-specific mortality 
[15,16,17,18, 33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54], 29 studies 
reported on long sleep duration and cancer-specific mortality 
[15,16,17,18, 33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57], and 
6 studies on short and long sleep duration for all-cause mortality within cancer survivors 
[16, 17, 50, 58,59,60]. Of the 32 included studies, 15 were conducted in the United States 
[16,17,18, 37, 38, 40, 44, 45, 47, 49, 50, 53, 55, 59, 60], nine in Asia (China, Japan, Korea, 
Singapore, and Taiwan) [15, 33, 34, 36, 39, 41, 48, 51, 52], and eight in Europe (Finland, 
Germany, Sweden, and the United Kingdom) [35, 42, 43, 46, 54, 56,57,58]. 
 
Table S1 summarizes the findings of the study quality assessment according to the Newcastle–
Ottawa Scale for observational studies. In general, the 32 studies included were of high quality. 
None of the 32 studies had low-quality ratings for the selection criteria including the 
representativeness of the exposed cohort, ascertainment of the exposure, and demonstration that 
the outcome was not present at start of study. Sleep duration was most commonly obtained via 
self-reported questionnaires, with only six studies receiving high-quality scores from utilizing 
objective measurements such as actigraphy. With respect to comparability, three of the 32 
studies were given poor quality ratings because it was unclear whether or not age had been 
adequately controlled for in the analysis. Additionally, two different studies were given poor 
quality ratings because they failed to control for other important factors, besides age, (e.g., sex, 
education, body mass index, physical activity treatment details, smoking history). All studies 
received high-quality ratings with respect to two of the three outcome criteria (assessment of the 
outcome and sufficient follow-up time); however, information on attrition and loss-to-follow-up 
was lacking in a large number of these studies and therefore, 16 of the 32 received poor quality 
ratings with respect to this criterion. 
 
Short sleep duration and mortality 
 
The forest plot for the association between short sleep duration and all-cancer-specific mortality 
is shown in Fig. 2. For all-cancer-specific mortality, there was a non-statistically significant 3% 
increased risk for individuals reporting the lowest sleep duration (typically 5–6 h/night) 
compared to reference ranges (HR = 1.03; 95% CI 1.00–1.06), with negligible heterogeneity 
(I2 = 0.8%). Results were similar across differences in sampling frames (HR = 1.03 vs. 1.04). 
 
Results for subgroup analyses according to cancer sites (all-cancer, lung, colorectal, breast, and 
prostate) and sex (male or female) are presented in Table 2. Within sex sub-groups for all-cancer, 
neither males nor females had statistically significant associations with cancer-specific mortality. 
In studies that investigated cancer-specific mortality for colorectal, breast, ovarian, or prostate 
cancers, there were non-statistically significant associations with low-moderate heterogeneity 
present (I2 ranging from 0.0 to 57.1%). Lung cancer was the only cancer site found to be 
associated with a statistically significant elevated risk of mortality (21.0%) in short duration 
sleepers (HR = 1.21; 95% CI 1.10–1.33). The statistically significant increased risk of lung 
cancer-specific mortality was maintained in stratified analyses by sex, and though estimates were 
not statistically different, males had a slightly higher magnitude of risk compared to females 
(HR = 1.24 vs. 1.17). 
Table 2. Results of subgroup meta-analysis for the association between short and long sleep duration with cancer-specific and all-
cause mortality 













95% CI I2 (%) 
Cancer-specific mortality 
Cancer site 
All-cancers 18 24 1.03 1.00–1.06 0.8 20 26 1.09 1.04–1.13 5.4 
Cancer-free baseline 11 16 1.03 0.98–1.07 10.6 12 17 1.06 1.02–1.11 0.0 
Otherb 7 8 1.04 0.99–1.11 0.0 8 9 1.18 1.05–1.33 32.5 
Female 12 12 1.03 0.98–1.08 0.0 13 13 1.13 1.03–1.23 25.9 
Male 10 10 1.01 0.92–1.11 24.0 11 11 1.10 1.05–1.16 7.8 
Lung 4 16 1.21 1.10–1.33 58.4 4 16 1.65 1.36–2.00 84.5 
Cancer-free baseline 3 15 1.20 1.09–1.33 61.2 3 15 1.65 1.35–2.03 85.5 
Otherb 1 1 1.23 0.91–1.67 – 1 1 1.58 1.06–2.35 – 
Female 4 9 1.17 1.02–1.35 56.6 4 9 1.51 1.18–1.93 73.2 
Male 3 8 1.24 1.09–1.43 60.8 3 8 1.79 1.32–2.43 89.6 
Colorectal 4 7 1.03 0.86–1.22 28.0 4 7 1.12 0.91–1.37 30.4 
Cancer-free baseline 3 6 1.00 0.82–1.23 37.1 3 6 1.04 0.88–1.24 0.0 
Otherb 1 1 1.18 0.75–1.85 – 1 1 2.17 1.24–3.80 – 
Female 3 4 0.97 0.79–1.19 0.0 3 4 1.27 0.71–2.28 77.5 
Male 1 2 0.90 0.67–1.20 0.0 2 3 1.09 0.82–1.44 0.0 
Breast 5 5 1.08 0.86–1.36 57.1 5 5 1.11 0.74–1.67 63.8 
Cancer-free baseline 2 2 1.23 0.82–1.82 55.7 2 2 0.59 0.36–0.97 0.0 
Otherb 3 3 0.98 0.77–1.26 44.3 3 3 1.49 1.18–1.89 0.0 
Ovarian 1 1 1.01 0.73–1.40 – 1 1 1.08 0.82–1.42 – 
Prostate 4 4 1.02 0.88–1.18 0.0 5 5 0.94 0.66–1.32 43.4 
All-cause mortality 
Cancer site 
Colorectal 2 2 1.13 0.91–1.40 8.8 2 2 1.01 0.83–1.24 0.0 
Breast 3 3 1.01 0.90–1.14 0.0 3 3 1.38 1.16–1.64 0.0 
Liver/pancreatic 1 1 1.29 0.37–4.47 – 1 1 3.35 0.74–15.15 – 
aStudies were represented only once in each pooled hazard ratio estimate, except when the published article only reported subgroup results (i.e., estimates by 
sex). In these instances, each subgroup was treated as a different study in random-effects models 
bIncludes studies that may incorporate individuals with pre-existing cancer diagnoses in sample 
 
Fig. 2. Forest plot for the association of short sleep duration and all-cancer-specific mortality, 
stratified by sampling frame 
 
In studies investigating all-cause mortality in colorectal, breast, or liver/pancreatic cancer 
survivors, there were no statistically significant associations with short sleep duration and 
mortality (HR = 1.13; 95% CI 0.91–1.40, HR = 1.01; 95% CI 0.90–1.14 and HR = 1.29; 95% CI 
0.37–4.47, respectively). 
 
Long sleep duration and mortality 
 
The forest plot for all-cancer-specific mortality related to long sleep duration is shown in Fig. 3. 
For all-cancer-specific mortality, there was an 9% increased risk for individuals reporting the 
longest sleep durations compared to recommended reference ranges (HR = 1.09; 95% CI 1.04–
1.13), with low evidence of heterogeneity (I2 = 5.4%). Studies that did not exclude individuals 
with pre-existing cancers displayed higher risk of mortality for long sleep duration compared to 
reference ranges than studies that were explicitly cancer-free at baseline (HRs 1.18 vs. 1.06), 
though results were not statistically different. When stratified by sex, all-cancer-specific 
mortality estimates continued to display statistically significant increased risk in both males and 




Fig. 3. Forest plot for the association of long sleep duration and all-cancer-specific mortality, 
stratified by sampling frame 
 
In subgroup analyses by cancer site, there was a 65% increased risk for lung cancer (HR = 1.65; 
95% CI 1.36–2.00). Further stratification of lung cancer-specific estimates by sex found that 
males (HR = 1.79; 95% CI 1.32–2.43) had an increased risk of mortality compared to females 
(HR = 1.51; 95% CI 1.18–1.93), though results were not significantly different. Colorectal, 
breast, ovarian, and prostate cancer sub-groups found non-statistically significant associations 
between cancer-specific mortality and long sleep duration with HRs of 1.12 (95% CI 0.91–1.37), 
1.11 (95% CI 0.74–1.67), 1.08 (95% CI 0.82–1.42), and 0.94 (95% CI 0.66–1.32), respectively. 
 
When evaluating all-cause mortality among cancer survivors, breast cancer survivors were found 
to have an increased risk of all-cause mortality associated with long sleep duration (HR = 1.38; 
95% CI 1.16–1.64). Colorectal and liver/pancreatic cancer survivors were not found to have 
statistically significant increased risk of all-cause mortality with HRs of 1.01 (95% CI 0.83–




When assessing heterogeneity using meta-regression modeling, sex and sampling frame were not 
found to a statistically significant source of heterogeneity in either short or long sleep durations 
by all-cancer or site-specific estimates where applicable. Heterogeneity by sex within all-cause 
mortality was unable to be assessed because of the limited number of studies. All included 
studies for all-cause mortality utilized the similar sampling frames, therefore heterogeneity 




Funnel plots for both short and long sleep durations in all-cancer-specific mortality are presented 
in Fig. 4. A visual examination of the funnel plot for short sleep duration shows a relatively 
symmetrical distribution of studies, with the both the Begg’s test (p = 0.99), and the Egger’s test 
(p = 0.14) indicating a lack of publication bias present. The funnel plot shows more asymmetry 
for long sleep duration, with fewer protective studies being published; however, the Begg’s test 
(p = 0.16), and the Egger’s test (p = 0.05) found that this asymmetry was only moderately 
supporting the presence of publication bias. 
 
 
Fig. 4. Funnel plots with the log hazards ratios (x-axis), log standard errors (y-axis), and pseudo 
95% confidence limits for short sleep duration (24 estimates) and long sleep duration (26 




This systematic review and meta-analysis suggests that both short and long sleep durations are 
associated with an increased risk of cancer mortality. More specifically, a statistically significant 
21% increased risk was found with short sleep duration and lung cancer-specific mortality. Long 
sleep duration was associated with a 9% increased risk of mortality from all-cancers, a 65% 
increased risk of lung cancer-specific mortality, and a 38% increase risk of all-cause mortality 
within breast cancer survivors. The discovery that some cancer sites (i.e., lung and breast) have 
significant associations with between sleep duration and mortality, while other sites (i.e., 
colorectal, prostate, ovarian and liver/pancreatic) do not suggests that these associations vary by 
cancer site and need to be considered separately rather than combining all-cancers together. It is 
also important to recognize that each cancer site has a distinct etiology, treatment regimens, side 
effects from treatments, and mortality rates [61]. The statistically significant finding between 
long sleep duration and all-cancer-specific mortality may exist because of higher proportions of 
lung cancer survivors included in these studies. Since the majority of the studies to date have not 
examined these associations by cancer site, it is not possible to conclude that there is an 
increased risk between long sleep duration and all-cancers. To understand these associations 
more fully, future studies need to examine these associations by cancer site. 
 
Our meta-analysis confirms findings from a published meta-analysis investigating the effect of 
short and long duration sleep durations on all-cancer-specific mortality, whereby significant 
results were found for long but not short sleep duration [10]. Our meta-analysis also presents 
estimates separated by cancer site and sex and sampling frame sub-groups within cancer sites, 
which have not yet been examined in previous meta-analyses. Additionally, this meta-analysis is 
the first to examine all-cause mortality within cancer survivors. Five of the six included studies 
with these estimates were published within the last year; hence, the study of sleep duration as a 
modifiable lifestyle factor for all-cause mortality within cancer survivors is gaining increased 
recognition [16, 17, 50, 58, 60]. 
 
Lung cancer-specific mortality was associated with both short and long sleep durations. Studies 
investigating lung cancer mortality and sleep duration produced estimates with substantial 
heterogeneity for both short and long sleep durations (I2 = 58.4% and 84.5%, respectively), 
suggesting that more research is needed to determine the true relation between sleep duration and 
lung cancer mortality. While sleep duration may not directly be the cause of mortality in this 
population, the comorbid conditions and side effects present within lung cancer survivors 
especially, have been associated with irregular sleep patterns. Some of the side effects 
experienced are respiratory symptoms, coughing, chest tightness, shortness of breath and have 
been related to poor sleep efficacy [62]. The mitigation of these comorbid conditions may help 
improve sleep hygiene and quality of life within this population. 
 
More robust associations were observed between long sleep duration and our mortality 
outcomes, including several subgroup analyses. The exact biological mechanisms whereby long 
sleep duration increases mortality risk in cancer survivors are largely unknown. However, long 
sleep duration has been previously associated with increased cause-specific mortality [5, 7] and 
all-cause mortality [3, 63] within the general population, and it has been speculated that 
individuals who sleep longer are often affected by a worsening physical condition, comorbidities, 
poor pre-existing health, depression, or reflecting the process of dying [64,65,66]. Furthermore, 
increased time in bed coupled with poor sleep quality/frequent awakenings throughout the night 
may confound the sleep–mortality risk association, since many participants may report time in 
bed rather than actual sleep duration [67, 68]. To date, we found only one study investigating the 
effects of sleep quality on mortality in cancer populations [18]. Further, there are currently no 
studies that have investigated the joint effects of sleep duration and quality on mortality 
outcomes in cancer populations, suggesting that future studies are needed to investigate these 
associations further. The potential biological mechanisms whereby short sleep duration 
influences mortality are less known compared to those related to long sleep duration. In general, 
long sleep durations pose greater risks of mortality for the reasons previously explained; 
however, studies have found elevated inflammatory processes and altered metabolic processes 
(e.g., increased orexigenic hormones and cortisol release, altered glucoregulatory 
responses/insulin resistance) in short duration sleepers [69,70,71,72], which may increase 
mortality risk. 
 
This study has several notable strengths. First, our literature search strategy was comprehensive 
and included a large number of cancer survivors from 32 studies, providing substantial power to 
detect even weak associations between sleep duration and mortality. Moreover, this review 
includes twice as many studies as a recent review on the topic, because of the broadened 
inclusion criteria investigating any cancer site [10]. Secondly, our study quality appraisal was 
rigorous and the studies included were determined to be of moderate-to-high quality. Third, 
minimal heterogeneity was observed for both long and short sleep duration suggesting that these 
studies are comparable and pooled associations reflect true associations. While various cut-off 
points were used to define short and long sleep durations, there was consistency overall in 
defining recommended sleep durations and identifying short and long sleep durations across the 
included studies. Finally, we conducted an extensive number of subgroup analyses by both sex 
and cancer site. 
 
Several limitations should also be considered when interpreting the results of this study. First, we 
were unable to confirm whether or not sleep duration was affected by other underlying health 
conditions since not all included studies adequately controlled for the presence of comorbid sleep 
disorders or other comorbidities that may impact sleep duration. Second, many studies use self-
reported measurements of sleep duration which may lead to exposure misclassification. Third, 
though sampling frame was not a statistically significant source of heterogeneity in our analyses, 
differences in estimates by exposure timing exist which need to be accounted for in future 
studies and acknowledged when comparing estimates across studies with different sampling 
frames. Finally, the impact of disease stage could not be assessed since few of the included 
studies adjusted for stage and none of the included studies presented stratified analyses by stage. 
Efforts to mitigate this limitation in future studies are warranted since disease stage is associated 
with both sleep disturbances [73] and mortality [74]. 
 
In conclusion, this review is the first to investigate the association of short and long sleep 
duration with cancer-specific mortality by cancer site, as well as all-cause mortality among 
cancer survivors. Both short and long sleep duration were associated with increased mortality, 
though estimates were greater for long sleep duration. Additional large-scale prospective studies 
are warranted to help understand this relation, especially those investigating cancer site-specific 
estimates since there is evidence that sleep may be a modifiable risk factor for reducing mortality 




CI: Confidence interval 
HR: Hazard ratio 
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